JNJ
NYSEJohnson & Johnson
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-28
Revenue & Earnings — fiscal year
$78.7B
2022
$80.0B
2023
$85.2B
2023
$88.8B
2024
$94.2B
2025
Snapshot
SEC EDGAR · FY 2025-12-28Revenue$94.2B
Net Income$26.8B
Gross Profit$63.9B
Oper Income$21.6B
EPS (dil)$11.03
Rev/sh$39.13
FCF/sh$8.18
Book/sh$33.87
Gross M67.9%
Oper M22.9%
Profit M28.5%
FCF M20.9%
ROE32.9%
ROA13.5%
ROIC15.9%
R&D/Rev0.1%
Rev Y/Y6.0%
Rev 3Y CAGR5.6%
EPS Y/Y90.5%
EPS 3Y CAGR17.9%
FCF 3Y CAGR4.7%
Payout—
Div/sh—
Shs Chg Y/Y0%
Current Ratio1.03
Quick Ratio0.77
Debt/Eq0.61
Int Coverage22.2×
Net Debt$30.2B
Total Debt$49.9B
Cash & Eq$19.7B
Total Assets$199.2B
Oper CF$24.5B
Capex$4.8B
Free CF$19.7B
Buybacks$6.0B
Equity$81.5B
Liabilities$117.7B
Shs Outstand2.41B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $78.7B | $80.0B | $85.2B | $88.8B | $94.2B |
| Gross Profit | $55.3B | $55.4B | $58.6B | $61.4B | $63.9B |
| Operating Income | — | — | — | — | — |
| Net Income | $20.9B | $17.9B | $35.2B | $14.1B | $26.8B |
| Diluted EPS | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 |
| Operating Cash Flow | $23.4B | $21.2B | $22.8B | $24.3B | $24.5B |
| Free Cash Flow | $19.8B | $17.2B | $18.2B | $19.8B | $19.7B |
COMMUNITY · $JNJ0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.